Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue

Published:November 11, 2021DOI:


      • CDR2L is expressed in Purkinje cells and large neurons scattered in the brain stem in adult rat and human brain.
      • CDR2L antigen expression is not sufficient for cells to become a target for the immune response in Yo-associated PCD.
      • CDR2 is detected in vascular smooth muscle cells and in ependymal cells lining the ventricle system in rat brain.


      Patients with ovarian cancer and paraneoplastic cerebellar degeneration, a cancer-related immune disorder, often have anti-Yo antibody. Here we studied the distributions of anti-Yo antigens CDR2L and CDR2 in rat and human brain using immunohistochemistry and western blot.
      CDR2L localized mainly to the Purkinje cells and large neurons scattered in the brain stem. CDR2 was detected in vascular smooth muscle cells of rat and human and in cells lining the ventricle system in rats.
      The observed distribution of CDR2L is compatible with the hypothesis that this antigen is the major target of anti-Yo. CDR2 and CDR2L are expressed by different cell subtypes.

      Graphical abstract



      PCD (paraneoplastic cerebellar degeneration), CDR1 (cerebellar degeneration-related protein 1), CDR2 (cerebellar degeneration-related protein 2), CDR2L (cerebellar degeneration-related protein 2-like), CNS (central nervous system), CSF (cerebrospinal fluid), FFPE (formalin-fixed and paraffin-embedded), IF (immunofluorescence), IHC (immunohistochemistry), PFA (paraformaldehyde), PBS (phosphate-buffered saline)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Altermatt H.J.
        • Rodriguez M.
        • Scheithauer B.W.
        • Lennon V.A.
        Paraneoplastic anti-Purkinje and type I anti-neuronal nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells.
        Lab. Investig. 1991; 65: 412-420
        • Anderson N.E.
        • Rosenblum M.K.
        • Posner J.B.
        Paraneoplastic cerebellar degeneration: clinical-immunological correlations.
        Ann. Neurol. 1988; 24: 559-567
        • Brain W.R.
        • Daniel P.M.
        • Greenfield J.G.
        Subacute cortical cerebellar degeneration and its relation to carcinoma.
        J. Neurol. Neurosurg. Psychiatry. 1951; 14: 59-75
        • Corradi J.P.
        • Yang C.
        • Darnell J.C.
        • Dalmau J.
        • Darnell R.B.
        A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues.
        J. Neurosci. 1997; 17: 1406-1415
        • Dropcho E.J.
        • Chen Y.T.
        • Posner J.B.
        • Old L.J.
        Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration.
        Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 4552-4556
        • Eichler T.W.
        • Totland C.
        • Haugen M.
        • Qvale T.H.
        • Mazengia K.
        • Storstein A.
        • et al.
        CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration.
        PLoS One. 2013; 8e66002
        • Fathallah-Shaykh H.
        • Finizio J.
        • Ho A.
        • Rosenblum M.K.
        • Posner J.B.
        Cloning and Characterization of a Second Leucine Zipper Protein Recognized by the Sera of the Patients with Antibody Associated Paraneoplastic Cerebellar Degeneration.
        • Furneaux H.M.
        • Dropcho E.J.
        • Barbut D.
        • Chen Y.T.
        • Rosenblum M.K.
        • Old L.J.
        • et al.
        Characterization of a cDNA encoding a 34-kDa Purkinje neuron protein recognized by sera from patients with paraneoplastic cerebellar degeneration.
        Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 2873-2877
        • Furneaux H.M.
        • Rosenblum M.K.
        • Dalmau J.
        • Wong E.
        • Woodruff P.
        • Graus F.
        • et al.
        Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration.
        N. Engl. J. Med. 1990; 322: 1844-1851
        • Greenlee J.E.
        • Brashear H.R.
        Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma.
        Ann. Neurol. 1983; 14: 609-613
        • Greenlee J.E.
        • Brashear H.R.
        • Herndon R.M.
        Immunoperoxidase labelling of rat brain sections with sera from patients with paraneoplastic cerebellar degeneration and systemic neoplasia.
        J. Neuropathol. Exp. Neurol. 1988; 47: 561-571
        • Herdlevaer I.
        • Kråkenes T.
        • Schubert M.
        • Vedeler C.A.
        Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
        Ann. Clin. Transl. Neurol. 2020; 7: 2231-2242
        • Hwang J.Y.
        • Lee J.
        • Oh C.K.
        • Kang H.W.
        • Hwang I.Y.
        • Um J.W.
        • et al.
        Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegeneration.
        Cell Death Dis. 2016; 7e2240
        • Jaeckle K.A.
        • Graus F.
        • Houghton A.
        • Cardon-Cardo C.
        • Nielsen S.L.
        • Posner J.B.
        Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen.
        Ann. Neurol. 1985; 18: 592-600
        • Kråkenes T.
        • Herdlevaer I.
        • Raspotnig M.
        • Haugen M.
        • Schubert M.
        • Vedeler C.A.
        CDR2L is the major Yo antibody target in paraneoplastic cerebellar degeneration.
        Ann. Neurol. 2019; 86: 316-321
        • McKeon A.
        • Tracy J.A.
        • Pittock S.J.
        • Parisi J.E.
        • Klein C.J.
        • Lennon V.A.
        Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond.
        Arch. Neurol. 2011; 68: 1282-1289
        • Nardelli E.
        • Curro-Dossi B.
        • Rizzuto N.
        • Graus F.
        Autoimmune paraneoplastic cerebellar degeneration: immunohistological localization of antibody-binding sites.
        Clin. Neurol. Neurosurg. 1995; 97: 89-94
        • Peterson K.
        • Rosenblum M.K.
        • Kotanides H.
        • Posner J.B.
        Paraneoplastic cerebellar degeneration. I. a clinical analysis of 55 anti-Yo antibody-positive patients.
        Neurology. 1992; 42: 1931-1937
      1. R&D Systems, 2020. R&D Systems Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections. R&D Systems.

        • Raspotnig M.
        • Haugen M.
        • Thorsteinsdottir M.
        • Stefansson I.
        • Salvesen H.B.
        • Storstein A.
        • et al.
        Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
        Cancer Immunol. Immunother. 2017; 66: 1463-1471
        • Sakai K.
        • Mitchell D.J.
        • Tsukamoto T.
        • Steinman L.
        Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration.
        Ann. Neurol. 1990; 28: 692-698
        • Schubert M.
        • Panja D.
        • Haugen M.
        • Bramham C.R.
        • Vedeler C.A.
        Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
        Acta Neuropathol. 2014; 128: 835-852
        • Shams’ili S.
        • Grefkens J.
        • de Leeuw B.
        • van den Bent M.
        • Hooijkaas H.
        • van der Holt B.
        • et al.
        Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
        Brain. 2003; 126: 1409-1418
        • Small M.
        • Treilleux I.
        • Couillault C.
        • Pissaloux D.
        • Picard G.
        • Paindavoine S.
        • et al.
        Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
        Acta Neuropathol. 2018; 135: 569-579
        • Smith J.L.
        • Finley J.C.
        • Lennon V.A.
        Autoantibodies in paraneoplastic cerebellar degeneration bind to cytoplasmic antigens of Purkinje cells in humans, rats and mice and are of multiple immunoglobulin classes.
        J. Neuroimmunol. 1988; 18: 37-48
        • Storstein A.
        • Krossnes B.K.
        • Vedeler C.A.
        Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
        Acta Neurol. Scand. 2009; 120: 64-67
        • Tomimoto H.
        • Brengman J.M.
        • Yanagihara T.
        Paraneoplastic cerebellar degeneration with a circulating antibody against neurons and non-neuronal cells.
        Acta Neuropathol. 1993; 86: 206-211
        • Totland C.
        • Kråkenes T.
        • Mazengia K.
        • Haugen M.
        • Vedeler C.
        Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer.
        Oncotarget. 2018; 9: 23975-23986
        • Verschuuren J.
        • Chuang L.
        • Rosenblum M.K.
        • Lieberman F.
        • Pryor A.
        • Posner J.B.
        • et al.
        Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration.
        Acta Neuropathol. 1996; 91: 519-525